Transcript:

Cardiovascular complications are rapidly emerging as a major threat with Covid-19. And here's why. SARS-CoV-2, otherwise known as Covid-19, infects people by attaching to the Ace2 receptor, which is expressed in the lungs but most importantly also in the lining of the blood vessels called the endothelium. Scientists have discovered evidence of direct infection of the endothelial cells, which traverse all major organ systems in the body through close to 100,000 miles of blood vessels in an adult. Recruitment of immune cells then results in widespread endothelial dysfunction, causing inflammation in the endothelial cells.

Many patients, especially African-Americans, may have preexisting endothelial dysfunction, putting them at extraordinary risk of a poor outcome from Covid infection, and they also have low nitric oxide levels. This provides a strong rationale for therapies to stabilize the endothelium, especially in those vulnerable patients with endothelial cell dysfunction, which includes high blood pressure, diabetes, obesity, cardiovascular disease, and smoking, who are prone to poor outcome.

Many of these risk factors are associated with low nitric oxide levels. Nitric Oxide has a wide range of important functions, which include vasodilation, regulation of local cell growth, protection of the vessels from injury from circulating platelets and white blood cells, and so playing a crucial role in normal endothelial function. NOviricid is a novel nitric oxide-releasing drug in an FDA-approved clinical trial in African Americans to restore and replete nitric oxide in patients, and also correct endothelial cell dysfunction, and improve outcomes.

NOviricid is fast-acting with proven vasodilation and antiviral properties. NOviricid works immediately by boosting the amount of usable nitric oxide in the body as well as restoring the body's ability to make nitric oxide on its own. After half an hour of a single dose, there's a significant improvement in vascular compliance as measured by augmentation index, and after four hours, a statistically significant improvement in endothelial function.

Covid also increases platelet activity, increasing the risk of blood clots, causing strokes, heart attacks, and pulmonary embolism. An increase in nitric oxide by NOviricid may help prevent the risk of blood clots. Studies indicate that nitric oxide may also help reduce respiratory tract infection by inactivating viruses, inhibiting the replication in epithelial cells. NOviricid is a nitric oxide-releasing drug designed to be started early in the disease process right at the onset of symptoms in order to prevent the rapid progression of disease and need for hospitalization.

Ask a provider about an investigative study in African Americans recently diagnosed with Covid utilizing NOviricid today.